



## **EUSA PHARMA ANNOUNCES SUCCESSFUL COMPLETION OF EUROPEAN MUTUAL RECOGNITION PROCESS FOR ROPYDAN®**

**Doylestown PA, USA and Oxford, UK - 18 October 2007** – EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the successful conclusion of the European Mutual Recognition Procedure for Rapydan®. The procedure completed successfully at the "day 90" target date of 9 October 2007. Rapydan®, a rapid-onset anaesthetic patch, is EUSA's lead product in the large and growing pain market.

Rapydan® achieved regulatory approval in Sweden in January 2007 and is also marketed in the USA by Endo under the brand name Synera™. Rapydan® is a 70 mg/70 mg medicated plaster which combines two local anaesthetic agents, lidocaine and tetracaine. The key differentiator of Rapydan® is the inclusion in the patch of a heating element which aids the speed of onset and penetration of the anaesthesia. It is indicated for surface anaesthesia of the skin in connection with needle puncture in adults and children from 3 years of age.

Following the conclusion of the European Mutual Recognition process, national licences will be issued in all 18 additional countries included in the MRP submission application. EUSA expects to launch Rapydan® early in 2008.

"We are delighted to have received a positive outcome for Rapydan® within the expected timeframe," said **Bryan Morton, Chief Executive of EUSA Pharma**. "We continue to make rapid progress towards our goal of becoming a leading transatlantic specialty pharmaceutical company. Rapydan® represents a major opportunity in a key market and we look forward to leveraging value from our recently acquired pan-European sales force in the marketing of this exciting product."

**---ENDS---**

### **About EUSA Pharma Inc**

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has six products on the market, including the antibiotic surgical implant Collatamp® G, Erwinase® and Kidrolase® for the treatment of acute lymphoblastic leukemia, and Rapydan®, a rapid-onset anesthetic patch for which EUSA expects to receive Europe-wide approval in 2007. EUSA also has several products in late-stage development, notably Collatamp® G topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx® bupivacaine implant for local post-surgical pain control.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over \$225 million and completed a number of significant transactions, including the acquisitions of Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US and Canada, a pan-European presence covering



over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to maintain a strong focus on acquisitions and in-licensing within its specialist medical and geographic areas, in line with its ambition to create a \$1 billion company by the first half of the next decade.

For more information please visit [www.eusapharma.com](http://www.eusapharma.com).

### **About Rapydan<sup>®</sup>**

Rapydan<sup>®</sup> 70 mg/70 mg medicated plaster contains 70 mg of lidocaine and 70 mg of tetracaine together with a heat-releasing component. It is indicated for surface anaesthesia of the skin in connection with needle puncture in adults and children from 3 years of age, and for superficial surgical procedures on normal intact skin in adults. One or two (four in adults) plasters are applied 30 minutes before the procedure.

Rapydan<sup>®</sup> is contraindicated in patients with hypersensitivity to the active substances, to local anaesthetics, to para-aminobenzoic acid, to sodium borate or to any of the other excipients and should not be used on mucous membranes, on areas with a compromised skin barrier or close to the eyes. Caution is recommended in patients with significant hepatic, renal or cardiac impairment, and in subjects with increased sensitivity to systemic circulatory effects of lidocaine and tetracaine. Rapydan<sup>®</sup> contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions. The risk of additional systemic toxicity should be considered when Rapydan<sup>®</sup> is used in patients receiving other products containing local anaesthetic agents, or antiarrhythmic drugs. During pregnancy the lowest dose and shortest possible treatment period should be used.

In clinical studies the most commonly reported adverse drug reactions were local erythema, oedema, blanching and rash. These reactions were generally mild and transient, and disappeared after treatment. Allergic or anaphylactoid reactions associated with lidocaine, tetracaine or other ingredients in Rapydan<sup>®</sup> may occur.

### **Contacts**

#### **EUSA Pharma UK**

Bryan Morton, Chief Executive

+44 (0) 1865 784 255

#### **Financial Dynamics**

Julia Phillips / Emma Thompson

+44 (0) 20 7831 3113